Molecular Biology Reports

, Volume 46, Issue 1, pp 77–82 | Cite as

ARA lncRNA, is upregulated in liver and breast tumor tissues

  • Farzaneh Raeisi
  • Mahdieh Abolfathi
  • Raheleh Ahmadi-Naji
  • Sara Iranparast
  • Esmat Noshadi
  • Arvand Akbari
  • Esmaeil Mahmoudi
  • Mansoor Khaledi
  • Asghar ArshiEmail author
Original Article


Important regulatory roles of long non-coding RNAs (lncRNAs) have been recently found, and reported as useful biomarkers in cancer. To identify a potential expression of the new discovered lncRNA (ARA), during promotes cell proliferation, apoptosis inhibit, migration and cell cycle arrest, we firstly evaluate its expression in two cancer tissues (breast cancer and liver cancer) and then compared its variability expression in tumor versus non-tumor samples. Expression profile of ARA lncRNA was evaluated using qRT-PCR in paired tumor and marginal non-tumor samples collected from patients who had been referred to the Shiraz General. After RNA extraction from tissue samples, cDNA synthesis and RT-qPCR method were performed according to the protocols. ARA lncRNA expression level was calculated using 2−ΔΔCt method. Principal-component analysis followed by receiver operating characteristic curve analyses was performed to evaluate the diagnostic potential of selected lncRNA. Our data revealed a significant upregulation (P < 0.001) of ARA in breast and liver tumor tissues, in comparison to same patients non-tumor marginal samples. Also, there was a significant difference between the expression of ARA lncRNA in breast cancer and liver cancer patients (P < 0.05). In conclusion, the results of our study suggest a possible role of ARA lncRNA in proliferation of breast and liver tissues, as well as its potential usefulness as a novel diagnostic biomarker for breast and liver tumors.


LncRNA ARA Breast cancer Liver cancer 



The authors are grateful to the staffs of research deputy of Shahrekord University of Medial Sciences and Cellular and Molecular Research Center, Shahrekord University of Medical Sciences.

Author contributions

FR, MA, EM and SI; literature review, manuscript writing and data collection. AA; literature review and manuscript revision, EN, AA; manuscript revision and RA-N, MK; literature review.

Compliance with ethical standards

Conflict of interest

The authors declare they have no conflict of interest.

Ethical approval

All applicable international, national, and institutional guidelines for the care of human were followed.


  1. 1.
    Ilic M, Ilic I (2016) Epidemiology of pancreatic cancer. World J Gastroenterol 22:9694–9705. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Sighoko D, Hunt BR, Irizarry B et al (2018) Disparity in breast cancer mortality by age and geography in 10 racially diverse US cities. Cancer Epidemiol 53:178–183. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Seyfried TN, Huysentruyt LC (2013) On the origin of cancer metastasis. Crit Rev Oncog 18:43–73CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Chen W, Hoffmann AD, Liu H, Liu X (2018) Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precis Oncol 2:4. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Byler S, Goldgar S, Heerboth S et al (2014) Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res 34:1071–1077PubMedGoogle Scholar
  6. 6.
    Samulin Erdem J, Notø H, Skare Ø et al (2017) Mechanisms of breast cancer risk in shift workers: association of telomere shortening with the duration and intensity of night work. Cancer Med 6:1988–1997. CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kar P (2014) Risk factors for hepatocellular carcinoma in India. J Clin Exp Hepatol 4:S34–S42. CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pan H, Fu X, Huang W (2011) Molecular mechanism of liver cancer. Anticancer Agents Med Chem 11:493–499CrossRefPubMedGoogle Scholar
  9. 9.
    Jiang K, Al-Diffalha S, Centeno BA (2018) Primary liver cancers-part 1: histopathology, differential diagnoses, and risk stratification. Cancer Control. CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kaikkonen MU, Lam MTY, Glass CK (2011) Non-coding RNAs as regulators of gene expression and epigenetics. Cardiovasc Res 90:430–440. CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Lin C-P, He L (2017) Noncoding RNAs in cancer development. Annu Rev Cancer Biol 1:163–184. CrossRefGoogle Scholar
  12. 12.
    Schmitt AM, Chang HY (2016) Long noncoding RNAs in cancer pathways. Cancer Cell 29:452–463. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jiang M, Huang O, Xie Z et al (2014) A novel long non-coding RNA-ARA: adriamycin resistance associated. Biochem Pharmacol 87:254–283. CrossRefPubMedGoogle Scholar
  14. 14.
    Malhotra A, Jain M, Prakash H et al (2017) The regulatory roles of long non-coding RNAs in the development of chemoresistance in breast cancer. Oncotarget 8:110671–110684. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2–∆∆CT method. Methods 25:402–408. CrossRefGoogle Scholar
  16. 16.
    Shahryari A, Rafiee MR, Fouani Y et al (2014) Two novel splice variants of ARA, ARA-S1, and ARA-S2 are coupregulated with SOX2 and OCT4 in esophageal squamous cell carcinoma. Stem Cells 32:126–134. CrossRefPubMedGoogle Scholar
  17. 17.
    Tian Y, Zhang X, Hao Y et al (2014) Potential roles of abnormally expressed long noncoding RNA UCA1 and Malat-1 in metastasis of melanoma. Melanoma Res 24:335–341. CrossRefPubMedGoogle Scholar
  18. 18.
    He Y, Meng X-M, Huang C et al (2014) Long noncoding RNAs: novel insights into hepatocelluar carcinoma. Cancer Lett 344:20–27. CrossRefPubMedGoogle Scholar
  19. 19.
    Zhou H-L, Luo G, Wise JA, Lou H (2014) Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanisms. Nucleic Acids Res 42:701–713. CrossRefPubMedGoogle Scholar
  20. 20.
    Soreq L, Guffanti A, Salomonis N et al (2014) Long non-coding RNA and alternative splicing modulations in Parkinson’s leukocytes identified by RNA sequencing. PLoS Comput Biol 10:e1003517. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kung JTY, Colognori D, Lee JT (2013) Long noncoding RNAs: past, present, and future. Genetics 193:651–669. CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wapinski O, Chang HY (2011) Long noncoding RNAs and human disease. Trends Cell Biol 21:354–361CrossRefPubMedGoogle Scholar
  23. 23.
    Kondo Y, Shinjo K, Katsushima K (2017) Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Sci 108:1927–1933CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Cortés-Funes H, Coronado C (2007) Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol 7:56–60. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature B.V. 2018

Authors and Affiliations

  1. 1.Young Researchers and Elite Club, Shahrekord BranchIslamic Azad UniversityShahrekordIran
  2. 2.Department of Immunology, Basic Health Sciences InstituteShahrekord University of Medical SciencesShahrekordIran
  3. 3.Student Research CommitteeShahrekord University of Medical SciencesShahrekordIran
  4. 4.Department of ImmunologyAhvaz University of Medical SciencesAhvazIran
  5. 5.Department of Biology, Faculty of Science, Fars Science and Research BranchIslamic Azad UniversityMarvdashtIran
  6. 6.Department of Biology, Faculty of Science, Marvdasht BranchIslamic Azad UniversityMarvdashtIran
  7. 7.Medical Microbiology, Student Research CommitteeShahrekord University of Medical SciencesShahrekordIran
  8. 8.Young Researchers and Elite Club, Najafabad BranchIslamic Azad UniversityNajafabadIran

Personalised recommendations